Trident Lifeline Quarterly Results for Trading Insights
In Mar 2026, Trident Lifeline (TLL) reported revenue ₹50 Cr and net profit ₹7 Cr — revenue +38.9% YoY. For annual financials, live price and key ratios, visit TLL share price screener.
TLL Quarterly Results — Revenue, Profit & EPS Highlights
Trident Lifeline latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore TLL share price history to track price trends across different timeframes.
- Revenue of ₹50 Cr in Mar 2026 (+51.5% vs Sept 2025, +38.9% vs Mar 2025)
- Net Profit of ₹7 Cr in Mar 2026 (+40.0% vs Sept 2025, +16.7% vs Mar 2025)
- EBITDA of ₹13 Cr in Mar 2026 (+44.4% vs Sept 2025)
- Operating Margin of 23.0% in Mar 2026 (+1.0pp vs Sept 2025)
- Earnings Per Share of ₹5.81 in Mar 2026 (+36.1% vs Sept 2025)
Trident Lifeline Quarterly Results — Revenue, EBITDA, Net Profit & EPS
TLL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 50 | 33 | 36 | 25 | 30 | 51.5% | 38.9% |
| Net Profit (₹ Cr) | 7 | 5 | 6 | 3 | 5 | - | - |
| EBITDA (₹ Cr) | 13 | 9 | 10 | 7 | 10 | - | - |
| EPS (₹) | 5.81 | 4.27 | 6.15 | 2.66 | 3.72 | - | - |
| Operating Margin (%) | 23.0% | 22.0% | 25.0% | 22.0% | 20.0% | - | - |
TLL Share Price Trend — 1-Year Movement Across Quarterly Results
Trident Lifeline 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse TLL annual financials for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
TLL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Trident Lifeline latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹457,721.13 Cr | 1912.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 169.3 |
|
Divis Laboratories
Mar 2026 |
₹174,081.02 Cr | 6857.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 242.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹161,380.94 Cr | 4822.7 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 419.0 |
|
Cipla
Mar 2026 |
₹117,800.00 Cr | 1472.3 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 214.3 |
|
Zydus Life Science
Mar 2026 |
₹115,505.60 Cr | 1147.9 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 90.7 |
All amounts in ₹ Crores